

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

**Application Number**

10/767712

Filing Date

1/29/04

**First Named Inventor**

Coats et al.

**Group Art Unit**

1624

**Examiner Name**

KIFLE

Attorney Docket Number

ORT-1375-CIP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>James K. H.</i>	Date Considered	8/17/05
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/267,712
Filing Date	1/29/04
First Named Inventor	Coats et al.
Group Art Unit	1624
Examiner Name	KIFLE
Attorney Docket Number	ORT-1375-CIP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
D.K.		GUTKOWSKA, B., et al., "Synthesis of Some Amide Derivatives Of 3-Aminotropene with Potential Pharmacological Action. I." ACTA POL. PHARM., 1984, 41(6), 613-617.	
		BOYD, R.E., et al., "Synthesis and Binding Affinities of 4-Diarylaminotropenes a New Class of Delta Opioid Agonists." Bioorganic & Med. Chem. Lett., 2000, 10: 1109-1111.	
		THOMAS, J.B., et al., "4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: High Affinity, Selective Ligands for the Delta Opioid Receptor Illustrate Factors Important to Antagonist Activity." ORG. MED. CHEM. LETT., 2000, 10:1281-1284.	
		PATENT ABSTRACTS OF JAPAN Vol. 018, no. 443 (c-1239), 18 August 1994 (1994-08-18) - & JP 06 135965 A (TORAY IND INC), 17 May 1994 (1994-05-17) abstract.	

Examiner Signature	<i>[Signature]</i>	Date Considered	8/17/05
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

